Modifying Enzymes
New England Biolabs, Inc. AluI Methyltransferase – 100 units
AluI Methyltransferase modifies the cytosine residue (C5) of the sequence AGCT.
New England Biolabs, Inc. HhaI Methyltransferase – 1000 units
HhaI Methyltransferase modifies the internal cytosine residue (C5) of the sequence GCGC
New England Biolabs, Inc. α1-2 Fucosidase - 1000 units
a1-2 Fucosidase is a highly specific exoglycosidase that catalyzes the hydrolysis of linear 1-2 linked fucose residues from oligosaccharides
New England Biolabs, Inc. MscI – 1250 units
A restriction endonuclease that recognizes the sequence TGG_^CCA.
Discovery Life Sciences HUMAN UGT2B15 0.5ML@5MG/ML
BD Gentest, Human UGT2B15, Regulatory Status is RUO, 0.5mL@5mg/mL
Discovery Life Sciences UGT CONTROL 0.5ML@5MG/ML
BD Gentest, UGT Control, Regulatory Status is RUO, 0.5mL@5mg/mL
FUJIFILM Biosciences NUCLEASE P1
*Orders for this supplier are non-cancellable/non-returnable once they are processed.*
New England Biolabs, Inc. T4 Polynucleotide Kinase (3' phosphatase minus) – 1000 units
T4 Polynucleotide Kinase catalyzes the transfer and exchange of P from the gamma position of ATP to the 5 -hydroxyl terminus of double- and single-stranded DNA and RNA, as well as nucleoside 3'-monophosphates. This modified version exhibits full kinase activity with no 3' phosphatase activity.
American Research Products Inc ALPHA AMYLASE AND BETA AMYLASE
5000265539 ALPHA AMYLASE AND BETA AMYLASE
Cayman Chemical ANTIBODY KU-0058948 25mg
A PARP1 and PARP2 inhibitor (IC50s = 3.4 and 1.5 nM, respectively); selective for PARP1 over PARP3, PARP4, and tankyrase (IC50s = 40, 1,200, and >10,000 nM, respectively); selectively inhibits the survival of embryonic stem cells lacking Brca1 or Brca2 over embryonic stem cells expressing wild-type Brca1 or Brca2; decreases the survival and induces apoptosis in P39 and MUTZ-3 AML cells at 1 µM; potentiates MS-275-induced cytotoxicity in patient-derived AML cells at 5 nM; reduces survival in PTEN-deficient HCT116 cells but not those expressing wild-type PTEN or HCT116+/neo
Enzo Life Sciences MMP-14 (catalytic domain) (human), (recombinant) (10 µg)
Alternative name: Matrix metalloproteinase 14. Membrane type matrix metalloproteinase 1. MT-1 MMP. MW: 22.5 kDa. Formulation: Liquid. In 50mM TRIS, pH 7.5, containing 5mM calcium chloride, 300mM sodium chloride, 20µM zinc chloride, 0.5% Brij-35, and 30% glycerol. Source: Produced in E.coli. MMP-14, Membrane-Type Matrix Metalloproteinase 1, MT1-MMP catalytic domain from human cDNA. The enzyme consists of the catalytic domain of human MMP-14 (Tyr112-Arg298, NM_004995) with a C-terminal purification tag. This represents a naturally-occurring active form of MMP-14 which lacks the C-terminal hemopexin domain. MMPs lacking this domain cannot cleave native collagens; however, activity toward other targets such as gelatin. CASein, or peptide substrates is unaffected. Use/Stability: The enzyme is stable on ice for at least several hours. However, it is recommended that thawing and dilution of the enzyme be done within as short a time as possible before start of the assay.